Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services' subsidiary, Optival Health Solutions Private Limited, received a 20-day suspension order for the Drug License of its store located in Yashoda Nagar, Amravati, Maharashtra. The order was issued by the Assistant Commissioner & Licensing Authority, Food & Drug Administration, Amravati, under Rule 65 of the Drugs and Cosmetics Act, 1940, and was received on August 13, 2025. The company estimates a potential revenue loss of approximately Rs 15.60 lakhs from this suspension. The order pertains to a single store and the matter has been disclosed to the stock exchanges under SEBI Listing Regulations.
The financial impact is minimal at around Rs 15.60 lakhs, which is negligible for Medplus given its large store network. This is a routine regulatory action affecting only one store and is unlikely to materially affect the stock price or shareholder value.